Incidence of ocular side effects of topical β blockers in the Netherlands

• Published in: British journal of ophthalmology Vol. 84; no. 8; pp. 856 - 859
• Main Authors: Beek, L.M. van, Keizer, R.J.W. de, Polak, B.C.P, Elzenaar, P.R, Haeringen, N.J. van, Kijlstra, A
• Format: Journal Article
• Language: English
• Published: BMA House, Tavistock Square, London, WC1H 9JR BMJ Publishing Group Ltd 01.08.2000; BMJ
• Subjects: Administration, Topical; Adrenergic beta-Antagonists - administration & dosage; Adrenergic beta-Antagonists - adverse effects; Aged; Biological and medical sciences; Drug toxicity and drugs side effects treatment; Eye Diseases - chemically induced; Eye Diseases - epidemiology; Female; Humans; ID Lelystad, Institute for Animal Science and Health; ID-Lelystad, Instituut voor Dierhouderij en Diergezondheid; Male; Medical sciences; Netherlands; Netherlands - epidemiology; ocular side effects; Original articles - Clinical science; Pharmacology. Drug treatments; Prevalence; Prospective Studies; Surveys and Questionnaires; Toxicity: eye; uveitis; Uveitis - chemically induced; Uveitis - epidemiology; β blockers; Netherlands; Europe; Antiglaucomatous agent; Human; Toxicity; Ocular hypertension; Uvea disease; Incidence; Eye; Prospective; Eye disease; Chemotherapy; Treatment; Glaucoma (eye); Uveitis; Beta blocking agent
• ISSN: 0007-1161; 1468-2079
• DOI: 10.1136/bjo.84.8.856

BACKGROUND Several ocular side effects including uveitis, have been reported following topical β blocker treatment for glaucoma and ocular hypertension. The incidence of these side effects was investigated in the Netherlands. METHODS A prospective observational design was used whereby monthly questionnaires were sent to all practising ophthalmologists in the Netherlands during 3 consecutive months. Questionnaires were returned at the end of each month. Any patient whose topical β blocker therapy was altered because of an ocular reaction was noted on this questionnaire. Ophthalmologists who did not return their questionnaires were interviewed by telephone at the end of the study period. The number of patients using topical β blockers was derived from drug sales figures. RESULTS 70% (328/467) of the ophthalmologists in the Netherlands participated in the study. During the 3 month study period 34 cases were reported: 15 patients had periorbital dermatitis, in eight patients eyelids and conjunctiva were affected, in seven patients the conjunctiva was affected, and four patients had punctate keratitis. The calculated incidence of ocular side effects during topical β blocker therapy was 1.51 cases/1000 patient years. CONCLUSION Topical β blocker therapy is associated with few clinically important ocular side effects. No cases of uveitis were reported.